Search Results

Polydex Pharmaceuticals Limited held a Special Meeting on July 14, 2023 relating to a Plan of Arrangement involving Polydex Pharmaceuticals Limited, Biospectra International Inc., and Biospectra Canada Inc., that upon shareholder approval, Biospectra would acquire all of the outstanding common and preferred shares of the Company.

Polydex Pharmaceuticals Limited reports financial results for the first quarter of fiscal 2024, the period ended April 30, 2023.

Polydex Pharmaceuticals Limited announced that it has entered into a Plan of Arrangement agreement whereby BioSpectra, Inc. and BioSpectra Canada, Ltd will acquire all of the outstanding common and preferred shares of the Company for total consideration of $6,940,000, of which US$6,924,980.02 will be paid for 3,432,478 common shares outstanding and US$15,019.98 will be paid for 899,400 Class B Preferred shares outstanding.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.

Polydex Pharmaceuticals Limited reports financial results for the third quarter of fiscal 2023, the period ended October 31, 2022.